Silver Book Fact

Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.

Chestnut, Charles H., Arne Skag, Claus Christiansen, Robert Recker, Jacob A. Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C. Schimmer, and Pierre D. Delmas. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004; 19(8): 1241-9. http://www.ncbi.nlm.nih.gov/pubmed/15231010

Reference

Title
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Publication
J Bone Miner Res
Publication Date
2004
Authors
Chestnut, Charles H., Arne Skag, Claus Christiansen, Robert Recker, Jacob A. Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C. Schimmer, and Pierre D. Delmas
Volume & Issue
Volume 19, Issue 8
Pages
1241-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…